^
Association details:
| Biomarker: | TROP2 expression |
|---|---|
| Cancer: | Cervical Cancer |
| Drug: | Trodelvy (sacituzumab govitecan-hziy) (Topoisomerase I inhibitor, TROP-2-targeted antibody-drug conjugate) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
377 - Cervical carcinomas that overexpress human trophoblast cell-surface marker (Trop-2) are highly sensitive to the antibody-drug conjugate sacituzumab-govitecan
Published date:
03/29/2020
Excerpt:
Trop-2 positive cell lines showed high sensitivity to sacituzumab govitecan in vitro, with IC50 values in the range of 0.18 to 0.26 nM (P = 0.02 and P = 0.04 for CVX-8 and ADX-3, respectively)...Overall survival at 90 days was significantly improved in the sacituzumab govitecan group (P = 0.014). Sacituzumab govitecan may represent a novel class of active drugs for cervical cancer patients over-expressing Trop-2.
